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negative bacteriaAbstract Annulated pyrano[2,3-d]pyrimidine derivatives were synthesized with methoxy, hydro-
xyl, nitrile and bromine substituents in its skeleton and correlated by electronic effect of substituents
on the magnitude of antimicrobial activity. The different electron donating and electron withdraw-
ing substituents of the pyrano[2,3-d]pyrimidine derivatives exerted positive influence on its antimi-
crobial activity against some Gram positive and Gram negative bacteria such as, Bacillus cereus,
Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aureus and Escherichia coli, respectively.
Antibacterial screening revealed that the presence of heteroaryl, cyano and amino groups on pyrano
[2,3-d]pyrimidine skeleton increases its penetrating power on bacterial cell wall and becomes more
biologically active. All the pyrano[2,3-d]pyrimidine derivatives were characterized by IR, 1H NMR,
13C NMR and mass spectra.
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Certain nitrogen and oxygen annulated heterocycles have
received considerable attention in medicinal chemistry such
as, as inhibitors of PDE5 extracted from human platelets
(Piaz et al., 2002), HIV-1 reverse transcriptase (Sweeney
et al., 2008), human EPK2 (Takayoshi et al., 2006), and
cyclin-dependent kinase (Brana et al., 2005). Pyrimidine ringshave significant pharmacological importance as being an inte-
gral part of DNA and RNA in several biological processes
(Fayed et al., 2009; Abd El-Wahab, 2002; Nargund et al.,
1991) with various pharmaceutical activities such as antitumor
(Grivsky et al., 1980), antihypertensive (Bennett et al., 1981),
antibacterial (Ajmal et al., 2014a,b), antifungal (Bhat et al.,
2014) antileishmanial activity (Agarwal et al., 2005), antiplate-
let/analgesic (Bruno et al., 2004) and antiplatelet activity
(Bruno et al., 2001). Therefore for the preparation of these
molecules, large efforts have been taken toward the synthetic
manipulation of annulated uracils that occupy a distinct and
unique place in medicinal chemistry. These are synthesised
20 A.R. Bhat et al.using varied multicomponent reactions based on Knoevenagel
condensation, Michael addition followed by cyclodehydration
strategy and finally heterocyclization (Ziarani et al., 2014).
Multicomponent reactions (MCRs) have gained significant
interest in modern medicinal and combinatorial chemists
(Weber et al., 1999; Armstrong et al., 1996), due to powerful
bond forming efficiency, diversity-oriented synthesis (DOS),
simple reaction design, atom-economy, environmental con-
cerns, and the possibility to construct target compounds using
several assorted elements in a single chemical procedure
(Posner, 1986). The solvent and nature of inexpensive, mild,
and reusable catalyst for MCRs play an important role in
the synthesis and its selectivity of targeted products. Therefore,
one of these catalysts is dibutylamine (DBA) which has
received significant interest such as being highly reactive,
eco-friendly, inexpensive, readily available and non-toxic for
affording the corresponding products in excellent yields with
high selectivity (Kalla et al., 2014).
In continuation of the current research from our laboratory
to develop efficient multicomponent reactions (MCRs) for the
preparation of pyrimidine annulated bioactive molecules
(Ajmal et al., 2014a,b), we report here, the dibutylamine
(DBA) catalyzed efficient, simple and fast synthesis of antibac-
terial active pyrano[2,3-d]pyrimidine derivatives via one-pot
three-component domino Knoevenagel–Michael addition
reaction in aqueous media (Scheme 1). A correlation structure
and activity relationship of these compounds with respect to
drug-likeness, Osiris and Molinspiration calculations is
described and verified experimentally.
2. Materials and methods
All chemicals were obtained from Aldrich Chemical Co. and S.
D. Fine Chem. Co. and used without further purification.
Melting points were determined by the open capillary method
and were uncorrected. IR spectra were recorded on a Perkin–
Elmer 298 spectrophotometer using KBr pellet. 1H and 13C
NMR spectra were recorded using a Bruker instrument (1H
at 400 MHz and 13C at 100 MHz) in DMSO-d6 solvent and
tetramethylsilane as internal standard. Chemical shifts are
reported in ppm. Mass spectra were recorded on a Shimadzu
GC–MS-QP-2010 model using Direct Injection Probe tech-
nique. Reactions have been monitored by thin layer chro-
matography on 0.2-mm precoated plates of silica gel G60
F254 (Merck). All test microorganisms were obtained fromH O
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Scheme 1 General synthesis of substituted pyrano[2,3-d]pyrim-
idines 4(a–j).Microbiology Department, Lokmanya Tilak College, Ujjain,
Madhya Pradesh and were as follows: Bacillus cereus
(ATCC-14579), Staphylococcus aureus (NCTC-7447), Kleb-
siella pneumonia (UC57), Pseudomonas aureus (ATCC 27853)
and Escherichia coli (ATCC 14169). Streptomycin was used
as antimicrobial standard drug. Antimicrobial activity was
tested by the disk diffusion method (Barry, 1976-21).
2.1. General procedure for the synthesis of compounds 4(a–j)
Substituted aromatic aldehydes 1 (1 mmol), malononitrile 2
(1 mmol), barbituric acid 3 (1 mmol) and 20 mol% dibuty-
lamine (DBA) were taken in RB flask with 16 ml aqueous etha-
nol (10:6 ratio) and stirred for 43–129 min. The progress of the
reaction was monitored by TLC and the solid product was fil-
tered, washed with cold water and recrystallized from ethanol
to obtain pure pyrano[2,3-d]pyrimidine derivatives with excel-
lent yields (83–94%).
2.2. Spectral analysis
2.2.1. 7-Amino-5-(4-nitrophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-
1H-pyrano[2,3-d]pyrimidine-6-carbonitril 4a
White powder, Mp: 235–236 C; Yield: 83%; IR (KBr (mmax):
3411 (NH2), 3209, 3163 (NH), 2989 (CAH), 2206 (C„N),
1732 (C‚O), 1461 (C‚C); 1H NMR (400 MHz, DMSO-d6)
d= 13.01 (s, 1H, NH), 8.93 (s, 1H, NH), 7.94 (d,
J= 7.1 Hz, 2H, Ar-H), 7.47 (d, J= 7.1 Hz, 2H, Ar-H), 6.79
(s, 2H, NH2), 4.96 (s, 1H, CH) ppm;
13C NMR (100 MHz,
DMSO-d6) d= 176.47 (C‚O), 170.60 (CNH2), 153.93
(CONH), 151.36 (C‚O), 150.32 (C-14), 147.44 (C-11),
128.99 (C-12/C-16), 123.19 (C-13/C-15), 120.41 (C„N),
104.46 (C-5), 75.53 (C-9), 70.70 (C-10) ppm; –Ms. (m/z):
328.2 [M + H+].
2.2.2. 7-Amino-5-(3-nitrophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-
1H-pyrano[2,3-d]pyrimidine-6-carbonitril 4b
White powder, Mp: 239-241 C; Yield: 86%; (KBr, m cm1):
3314 (NH2), 3301, 3247 (NH), 2942 (CAH), 2212 (C‚N),
1605 (C‚O), 1476 (C‚C); 1H NMR (400 MHz, DMSO-d6)
d 12.02 (s, 1H, NH), 10.21 (s, 1H, NH), 8.38 (s, 1H, Ar‚H),
8.19 (d, J= 6.3 Hz, 2H, Ar‚H), 6.82 (s, 2H, NH2), 3.94 (s,
1H,CH); 13C NMR (100 MHz, DMSO-d6) d 166.12 (C‚O),
160.73 (CNH2), 157.01 (CONH), 151.56 (C‚O), 150.57
(C-14), 146.11 (C-11), 129.23 (C-12), 123.08 (C-13), 119.45
(C„N), 104.42 (C-5), 79.32 (C-9), 71.10 (C-10); –Ms. (m/z):
328.2 [M + H+].
2.2.3. 7-Amino-5-(2-nitrophenyl)-2,4-dioxo-2,3,4,5-tetrahydro-
1H-pyrano[2,3-d]pyrimidine-6-carbonitril 4c
White powder, Mp: 231–234 C; Yield: 84%; IR (KBr, m
cm1): 3302 (NH2), 3331, 3142 (NH), 2938 (CAH), 2172
(C‚N), 1645 (C‚O), 1527 (C‚C); 1H NMR (400 MHz,
DMSO-d6) d= 10.12 (s, 1H, NH), 10.79 (s, 1H, NH), 7.69–
7.63 (m, 3H, Ar‚H), 6.82 (s, 2H, NH2), 3.94 (s, 1H, CH)
ppm; 13C NMR (100 MHz, DMSO-d6) d= 179.44 (C‚O),
170.14 (CNH2), 159.59 (CONH), 156.79 (C‚O), 149.87 (C-
14), 134.52 (C-11), 132.12 (C-12), 130.05 (C-13), 127.31
(C„N), 91.81 (C-5), 84.24 (C-9), 57.01 (C-10) ppm; Ms.
(m/z): 350.02 [M + Na+].
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tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitril 4d
Yellow powder, Mp: 158–160 C; Yield: 94%; IR (KBr, m
cm1): 3457 (OH), 3260 (NH2), 3131, 3088, (NH), 2293
(CAH), 1729 (C„N), 1678 (C‚O), 1555 (C‚C); 1H NMR
(400 MHz, DMSO-d6) d= 10.87 (s, 1H, NH), 10.79 (s, 1H,
NH), 6.98 (d, J= 7.5 Hz, 2H, Ar‚H), 6.82 (s, 2H, NH2),
6.61 (d, J= 7.6 Hz, 2H, Ar‚H), 6.05 (s, 1H, OH), 4.31 (s,
1H, CH) ppm; 13C NMR (100 MHz, DMSO-d6) d= 168.93
(C‚O), 157.19 (C-14), 155.61 (CNH2), 153.38 (CONH),
152.72 (C‚O), 129.32–129.20 (C-12 & C-16), 118.20
(C„N), 115.16 (C-13), 97.22 (C-5), 58.65 (C-9), 54.87 (C-10)
ppm; Ms. (m/z): 298.06.
2.2.5. 7-Amino-5-(3-hydroxyphenyl)-2,4-dioxo-2,3,4,5-
tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitril 4e
Yellow powder, Mp: 169–171 C; Yield 91%; IR (KBr, m
cm1): 3439 (OH), 3337 (NH2), 3193, 3028 (NH), 2206
(CAH), 1677 (C‚N), 1625 (C‚O), 14741 (C‚C); 1H NMR
(400 MHz, DMSO-d6) d= 12.04 (s, 1H, NH), 10.62 (s, 1H,
NH), 6.97–6.83 (m, 3H, Ar‚H), 6.61 (s, 2H, NH2), 6.09 (s,
1H, OH), 3.94 (s, 1H, CH) ppm; 13C NMR (100 MHz,
DMSO-d6) d= 179.43 (C‚O), 170.23 (C-14), 159.49
(CNH2), 157.19 (CONH), 155.08 (C‚O), 129.31 (C-16),
129.20 (C„N), 115.15 (C-13), 93.41 (C-5), 84.21 (C-9), 52.03
(C-10) ppm; Ms. (m/z): 299.02 [M +H+].
2.2.6. 7-Amino-5-(4-bromophenyl)-2,4-dioxo-2,3,4,5-
tetrahydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitril 4f
White powder, Mp: 228–232 C; Yield: 89%; IR (KBr, m
cm1): 3370 (NH2), 3340, 3189 (NH), 3080 (CAH), 2220
(C‚N), 1684 (C‚O), 1567 (C‚C); 1H NMR (400 MHz,
DMSO-d6) d= 14.10 (s, 1H, NH), 13.01 (s, 1H, NH), 7.75
(d, J= 7.1 Hz, 2H, Ar‚H), 7.33 (d, J= 7.1 Hz, 2H, Ar‚H),
6.82 (s, 2H, NH2), 3.90 (s, 1H, CH) ppm;
13C NMR (100 MHz,
DMSO-d6) d 173.47 (C‚O), 160.34 (CNH2), 153.89 (CONH),
145.91 (C‚O), 138.53 (C-11), 131.97 (C-13 & C-15), 129.69
(C-12 & C-16), 124.03 (C-14), 121.28 (C„N), 105.25 (C-5),
69.60 (C-9), 50.10 (C-10) ppm; Ms. (m/z): 384.12 [M + Na+].
2.2.7. 7-Amino-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-
pyrano[2,3-d]pyrimidine-6-carbonitrile 4g
Yellow powder, Mp: 236–238 C; Yield: 94%; IR (KBr, m
cm1): 3371 (NH2), 3301, 3212 (NH), 3114 (CAH), 2129
(C„N), 1694 (C‚O), 1572 (C‚C) ppm; 1H NMR
(400 MHz, DMSO-d6) d= 10.98 (s, 1H, NH), 10.80 (s, 1H,
NH), 7.31 (t, J= 7.3 Hz, 2H, Ar‚H), 7.14–7.06 (m, 3H,
Ar‚H), 6.82 (s, 2H, NH2), 4.29 (s, 1H, CH) ppm;
13C
NMR (100 MHz, DMSO-d6) d= 160.39 (C‚O), 155.61
(CNH2), 153.91 (CONH), 151.36 (C‚O), 145.92 (C-11),
128.68 (C-12), 128.49 (C-13), 127.61 (C-14), 118.21 (C„N),
93.41 (C-5), 58.66 (C-9), 50.89 (C-10) ppm; Ms. (m/z): 283.08
[M + H+].
2.2.8. 7-Amino-5-(4-methoxyphenyl)-2,4-dioxo-1,3,4,5-
tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile 4h
Dark yellow powder, Mp: 289–293 C; Yield: 91%; IR (KBr, m
cm1): 3317 (NH2), 3282, 3145 (NH), 3063 (CAH), 2215(C„N), 1743 (C‚O), 1668 (C‚C); 1H NMR (400 MHz,
DMSO-d6) d= 10.98 (s, 1H, NH), 10.80 (s, 1H, NH), 7.14
(d, J= 7.5 Hz, 2H, Ar‚H), 6.86–6.82 (m, 4H, Ar‚H &
NH2), 4.16 (s, 1H, CH), 3.81 (s, 3H, OCH3) ppm;
13C NMR
(100 MHz, DMSO-d6) d= 161.99 (C‚O), 159.11 (C-14),
155.61 (CNH2), 151.97 (CONH), 151.36 (C‚O), 130.34
(C-11), 129.50 (C-12), 123.56 (C„N), 113.14 (C-13), 93.41
(C-5), 58.66 (C-9), 57.46 (CH3), 53.46 (C-10) ppm; Ms. (m/z):
313.01 [M +H+].
2.2.9. 7-Amino-5-(2-methoxyphenyl)-2,4-dioxo-1,3,4,5-
tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile 4i
Yellow powder, Mp: 301–303 C; Yield: 87%; IR (KBr, m
cm1): 3419 (NH2), 3202, 3137 (NH), 3016 (CAH), 2272
(C„N), 1765 (C‚O), 1609 (C‚C); 1H NMR (400 MHz,
DMSO-d6) d= 10.93 (s, 1H, NH), 10.71 (s, 1H, NH), 7.44
(d, J= 4.6 Hz, 1H, Ar‚H), 7.14–7.7.11 (m, 4H, Ar‚H &
NH2), 4.16 (s, 1H, CH), 3.73 (s, 3H, OCH3) ppm;
13C NMR
(100 MHz, DMSO-d6) d= 169.87 (C‚O), 161.02 (C-14),
158.21 (CNH2), 152.46 (CONH), 151.82 (C‚O), 131.15
(C-11), 129.09 (C-12), 124.02 (C„N), 113.18 (C-13), 94.39
(C-5), 58.93 (C-9), 57.41 (CH3), 53.57 (C-10) ppm; Ms.
(m/z): 313.05 [M +H+].
2.2.10. 7-Amino-5-(3,4-dimethoxyphenyl)-2,4-dioxo-1,3,4,5-
tetrahydro-2H-pyrano[2,3-d]pyrimidine-6-carbonitrile 4j
Yellow powder, Mp: 312–314 C; Yield: 93% ; IR (KBr, m
cm1): 3194 (NH2), 3103, 2223 (NH), 1734 (CAH), 1662
(C„N), 1576 (C‚O), 1262 (C‚C); 1H NMR (400 MHz,
DMSO-d6) d= 10.98 (s, 1H, NH), 10.80 (s, 1H, NH), 6.83–
6.80 (m, 5H, Ar‚H & NH2), 4.29 (s, 1H, CH), 3.83 (s, 3H,
OCH3), 3.75 (s, 3H, OCH3) ppm;
13C NMR (100 MHz,
DMSO-d6) d= 164.65 (C‚O), 155.61 (CNH2), 153.94
(CONH), 151.97 (C‚O), 149.25 (C-14), 148.54 (C-13),
131.34 (C-11), 126.92 (C-16), 119.53 (C„N), 116.52 (C-12),
114.27 (C-15), 93.40 (C-5), 58.66 (C-9), 57.91 (CH3), 56.78
(CH3), 51.23 (C-10) ppm; Ms. (m/z): 342.
2.3. Biological evaluation
All the products were dissolved in N,N-dimethylformamide
(DMF) for dilution to prepare stock solutions of 20 mg/mL
for antimicrobial assay. Agar plates were uniformly surface
inoculated with fresh broth culture of Gram positive and neg-
ative bacteria such as B. cereus (ATCC-14579), S. aureus
(NCTC-7447), K. pneumonia (UC57), P. aureus (ATCC
27853) and E. coli (ATCC 14169). These impregnated disks
were placed on medium suitably spaced apart and plates were
incubated at 30 C for 1 h to permit good diffusion and were
then transferred to an incubator at 37 ± 2 C for 24 h. The
zones of inhibition were measured on mm scale. Streptomycin
was used as standard antimicrobial drug. Antimicrobial activ-
ity test results are shown in Table 3. All the synthesized pyrano
[2,3-d]pyrimidine derivatives showed good antimicrobial activ-
ity, due to similarity of synthesized compounds to the sub-
strate of targeted enzyme. The compounds with electron
donating group at the different positions on phenyl ring have
subsequent hydrophobic interaction with active site of enzyme
increase the antibacterial activity.
Table 1 Effect of catalysts and solvents for model product 4d using aqueous ethanol.a
Entry Catalyst Catalyst (mol%) Time (mins) Yield (%)b Solvent Time (mins) Yield (%)b
1 N-methylamidazole 20 114 79 EtOH–H2O 53 94
2 Triethylamine 20 83 90 DMF 59 61
3 Piperidine 20 110 71 CH2Cl2 103 58
4 Morpholine 20 140 68 1,4-Dioxane 72 63
5 Dibutylamine 5 105 74 Solvent-free 192 57
6 Dibutylamine 10 68 86 EtOH 45 87
7 Dibutylamine 15 53 87 H2O 68 83
8 Dibutylamine 20 53 94
9 Catalyst free – 189 37
a Reaction conditions: hydroxybenzaldehyde (1 mmol), malononitrile (mmol), barbituric acid (1 mmol), catalyst DBA 20 mol%, stirring/
reflux, r.t.
b Isolated yields.
Table 2 Comparative synthesis of pyrano[2,3-d]pyrimidines using DBA catalyst versus reported literature.
Entry Catalyst Solvent Condition Time Yield (%) Reference
1 DABCO EtOH: H2O Reflux 30–40 min 82–94 Ajmal et al. (2014a,b)
2 Catalyst-free H2O MW 3–5 min 82–94 Bhat et al. (2014)
3 Catalyst-free H2O 60 C 1–4 h 71–86 Bhat et al. (2014)
4 Catalyst-free H2O 48 C 2–5 h 69–83 Bhat et al. (2014)
5 SBA-Pr-SO3H Solvent-free 60 C 5–45 min 69–86 Ziarani et al. (2014)
6 Catalyst-free Solvent-free Ball-milling 30–90 min >99 Sara and Naimi-Jamal (2009)
7 Catalyst-free H2O MW 3–5 min 86–94 Yuan et al. (2004)
8 DBA EtOH: H2O Reflux 53 min 94 Present Work
Scheme 2 Plausible mechanism for the synthesis of pyrano[2,3-
d]pyrimidines.
22 A.R. Bhat et al.3. Results and discussion
Herein, we report the synthesis of annulated pyrano[2,3-d]
pyrimidine derivatives via one pot three component domino
Knoevenagel–Michael addition reaction. In initial studies, we
found the base catalysts such as N-methylamidazole, triethy-
lamine, piperidine, morpholine and dibutylamine (Table 1,
entries 1–8), were equally competent in furnishing the desired
model product 4 in good yields. Among these basic catalysts,
20 mol% of dibutylamine (DBA) gave the best result in terms
of time of completion and the product yields 94% (Table 1,
entry 8). In the absence of catalyst, the reaction was completed
after 189 min of reflux (Table 1, entry 9) and yield of product
obtained only 37%. Therefore, dibutylamine (DBA) catalyst
appears to be superior to any of the other tested catalysts. Fur-
ther, we focused on systematic evaluation of different solvents
like ethanol: H2O, DMF, CH2Cl2 and 1,4-Dioxane (Table 1,
entry 1–5), for the synthesis of model product 4. We found that
the best conversion was observed when the reaction was pro-
ceeded in Ethanol: H2O (Table 1, entry 1). The reported liter-
ature revealed the synthesis of pyrano[2,3-d]pyrimidine
derivatives under different conditions. The overall reported
result was compared with DBA catalyst (Table 2, entry 1–8).
Plausible mechanism for the synthesis of pyrano[2,3-d]
pyrimidines is shown in Scheme 2.
The different substituents of the phenyl, OH, OCH3, NO2
and Br group on annulated pyrimidines are very essential for
activity against some Gram positive and Gram negative bacte-
ria (Kamlesh et al., 2014). These substituents have further
showed extensive effect on the membrane potential associated
with bactericidal activity (Vinita et al., 2014). The relevant
studies showed that steric, electronic effects and polarparameters of the phenyl in pyrano[2,3-d]pyrimidine were
important for antimicrobial activity (Table 3). These findings
suggest that rather than disrupting cell membranes, the
compounds acted outside the cell and became attached to
surface groups of the bacterial cells increases its activity.
Compound 4g exhibited broad-spectrum activity against
B. cereus, P. aureus and E. coli bacteria, Compound 4e showed
maximum antimicrobial activity against S. aureus, P. aureus
and E. coli, Compound 4d showed activity against B. cereus,
Compound 4h and 4i exhibited maximum activity against
Table 3 Antibacterial activity of annulated pyrano[2,3-d]
pyrimidine derivatives 4(a-j).
Compd. R Zones of inhibition*
Gram positive Gram negative
A B C D E
4a 4-NO2 11 4 4 3 12
4b 3-NO2 14 7 6 11 11
4c 2-NO2 10 5 6 9 11
4d 4-OH 14 15 10 15 15
4e 3-OH 10 15 8 15 14
4f 4-Br 4 12 3 4 6
4g H 12 8 5 14 13
4h 4-OCH3 11 14 14 5 8
4i 2-OCH3 11 15 13 7 9
4j 3,4-OCH3 13 8 14 8 12
SD – 16 18 18 16 18
SD: Streptomycin, A = Bacillus cereus (ATCC-14579), B =
Staphylococcus aureus (NCTC-7447), C = Klebsiella pneumonia
(UC57), D = Pseudomonas aureus (ATCC 27853), E = E. coli
(ATCC 14169).
* Inhibition zone around the disks for antibacterial activity:
11–18 mm: very strong activity; 5–10 mm: moderate activity;
1–4 mm: weak activity.
Figure 1 Antibacterial activity of annulated pyrano[2,3-d]pyrim-
idine derivatives.
Table 4 Osiris calculations of compounds 4(a–j) and standard refe
Compd. Toxicity risksa
MUT TUMO IRRI RE
4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
Strept
: not toxic; : slightly toxic; : highly toxic.
a MUT: mutagenic; TUMO: tumorigenic; IRRI: irritant; REP: reprodu
b CLP: cLogP, S: Solubility, DL: Druglikeness, DS: Drug-Score.
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pound 4j showed maximum activity against B. cereus, K. pneu-
monia and E. coli. Electron withdrawing groups reduced
antimicrobial activity due to decreasing partial charge on
nitrogen atoms of barbiturate moiety on pyrano[2,3-d]
pyrimidine ring, leads to a decrease the antimicrobial activity.
Compounds 4a, 4b and 4c were found to have good activity
against B. cereus and K. pneumonia, compound 4c showed also
activity against P. aureus and compound 4f exhibited maxi-
mum activity against S. aureus (Table 3 and Fig. 1). The annu-
lated pyrano[2,3-d]pyrimidine products as antimicrobial
agents are excellent derivatives for drug resistance issues in
clinically used therapeutics and furnish motivating model for
studying interaction with antimicrobial targets, as possible
charge modification of the substituents and O/N of pharma-
cophore groups present in the skeleton.
The results of the present study revealed the following order
of bactericidal activity intensities elicited by the annulated
pyrano[2,3-d]pyrimidine derivatives: 4-OH> 3-OH>
4-OCH3 > -H> 2-OCH3 > 3,4-OCH3 > 4-NO2 > 3-NO2 >
2-NO2 > 4-Br. It is found that the negative and positive
charges of the nitrogen of the CN group and hydrogen of
the NH group contribute positively in favor of an antibacterial
activity, and this is in good agreement with the mode of
antibacterial action of the compounds bearing (Xd–Yd+)
pharmacophore site. It was hypothesized by Osiris calculations
software that difference in charges between two terminal
groups of dipolar pharmacophore site (Xd–Yd+) may facili-
tate the inhibition of bacteria, more than viruses. It is further
found that the activity decreases with a decrease in negative
charge of the CN group of the common pharmacophore
fragment of the series 4(a–j) (HN–CN) Table 4. Further the
prediction results of compounds 4(a–j) on the basis of molec-
ular properties (TPSA, GPCR ligand and ICM) are valued
by Molinspiration calculations software (Table 5). The compu-
tational analysis such as drug-likeness, Osiris and Molinspira-
tion calculations were used for the targeted bio active pyrano
[2,3-d]pyrimidine derivatives.rence.
Drug-scoreb
P CLP S DL DS
0.42 6.14 10.59 0.29
0.42 6.14 10.59 0.29
0.42 6.14 10.59 0.29
0.25 5.38 0.20 0.49
0.25 5.38 0.69 0.45
1.25 6.51 2.22 0.30
0.55 5.68 0.30 0.46
0.45 5.70 0.35 0.45
0.45 5.70 0.35 0.45
0.34 5.71 1.25 0.55
7.83 0.96 0.83 0.43
ctive effective.
Table 5 Molinspiration calculations of molecular properties and drug-likeness of compounds 4(a–j) and standard reference.
Compd. Molecular properties calculationsa Drug-likenessb
MW (g/mole) TPSA OH–NH interact. Violation ROTB VOL GPCRL ICM KI NRL PI EN
4a 327 171 4 0 2 257 1.36 1.34 1.23 0.91 1.38 0.81
4b 327 171 4 0 2 257 1.37 1.36 1.22 0.91 1.39 0.83
4c 327 171 4 0 2 257 1.38 1.35 1.32 0.92 1.50 0.86
4d 298 145 5 0 1 242 1.27 1.35 1.14 0.74 1.37 0.69
4e 298 145 5 0 1 242 1.28 1.37 1.16 0.74 1.38 0.69
4f 361 125 4 0 1 252 1.43 1.49 1.24 1.02 1.51 0.83
4g 282 125 4 0 1 234 1.41 1.47 1.27 0.97 1.48 0.78
4h 312 134 4 0 2 259 1.29 1.42 1.16 0.86 1.35 0.76
4i 312 134 4 0 2 259 1.31 1.45 1.21 0.86 1.44 0.79
4j 342 143 4 0 3 285 1.20 1.32 1.07 0.82 1.25 0.71
Streptc 581 336 16 3 9 497 0.09 0.16 0.17 0.18 0.65 0.38
a TPSA: total polar surface area, O/NH: O–HN interaction, Violation: number of violation, VOL: volume.
b GPCR: GPCR ligand, ICM: Ion channel modulator, KI: Kinase inhibitor, NRL: nuclear receptor ligand, PI: protease inhibitor, EN:
enzyme inhibitor.
c Strept: Streptomycin.
24 A.R. Bhat et al.4. Conclusion
The antimicrobial study revealed that targeted compounds
were more active with OH than the OCH3 group, irrespective
of the position of substitution on the benzene ring. Since
hydrophobic property is important for the drugs to diffuse
through the pathogenic biological system. The different elec-
tron withdrawing subsistents of the pyrano[2,3-d]pyrimidine
skeleton exerted less influence on its antimicrobial activity
against some Gram positive and Gram negative bacteria like
P. aureus, E. coli, S. aureus, K. pneumonia and B. cereus. Hence,
this study have supportive for the medicinal chemists in under-
standing antimicrobial activity of annulated pyrano[2,3-d]
pyrimidine products, one with different inter atomic distances
(linkers) steric, electronic effects, polar parameters and with
different electronic environments. The anti-Kinase pharma-
cophore site (O‚CANHAC‚O) should be evaluated in com-
ing step as continuation of these investigations on this series.Conflict of interest
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